European Pharmaceutical Review

DECEMBER 22, 2022

2 A bsAb can have clinical advantages over conventional monoclonal antibodies (mAbs) including targeting functionally interrelated checkpoint inhibitors, directing immune responders to cancer cells, enhancing specificity and decreasing off-target toxicity. 2017 Aug 1;28(8):2009-2012. Available at: doi.org/10.1016/j.ctrv.2021.102240.

Biosimilars 98

Biosimilars Immunity Immunization Drug Development 98

PharmaShots

JUNE 28, 2023

In 2009, Pfizer acquired Wyeth thus seeking the rights to Enbrel. Some of the alternative drugs for Enbrel include: Enbrel’s Biosimilars6 As Enbrel has a long journey in the market it is already facing competition from biosimilars in the US and other countries. Enbrel biosimilars Gabionline.net Centerforbiosimilars.com 7.

Biosimilars 40

Biosimilars Insurance Coverage and Processing Dosage Compounding 40

PharmaShots

MARCH 29, 2023

Some companies accept the offered period and open doors to biological drugs or biosimilars. Though the exact working of Actemra in the body is not known, from early research, it is suggested that Actemra blocks the connecting of IL-6 protein to the cells and prevents overactivity of the immune system.

Biosimilars 49

Biosimilars Diabetes Chemotherapy Immunity 49